Home

The first micronised progesterone licensed for adjunctive use with oestrogen in postmenopausal women with an intact uterus as HRT in the UK.1,19-22 About Utrogestan (micronised progeserone) 100mg
Request a visit from a Besins Healthcare Representative
Watch video educational series
Request your Utrogestan 100mg patient pad
Request your HRT Products leave piece
Feedback Survey

Utrogestan (micronised progesterone) 100mg is indicated for adjunctive use with oestrogen in postmenopausal women with an intact uterus, as hormone replacement therapy (HRT).1

Body identical micronised progesterone greatly reduces oestrogen-induced risk of endometrial cancer in women with an intact uterus.1,2,3

  • Each capsule of Utrogestan 100mg contains 100mg of micronised progesterone, identical to the hormone produced by the body1,2
  • The first micronised progesterone licensed for adjunctive use with oestrogen in postmenopausal women with an intact uterus as HRT in the UK1,19-22
  • The ability to individualise HRT treatment by offering a separate micronised progesterone and allowing the tailoring of the oestrogen component for vasomotor symptom control1,23

Impact on bleeding patterns

In a randomised, double-blind, placebo-controlled trial, bleeding pattern comparisons made between conjugated equine oestrogen + cyclical medroxyprogesterone acetate (MPA) (n=118) and conjugated equine oestrogen + cyclical micronised progesterone (n=120) arms.24

Reduction in blood flow versus MPA + oestrogen (over 3 years; p≤0.05)24

Reduction in number of bleeding days versus MPA + oestrogen (over 3 years; p≤0.01)24

Dosing

Offers individualisation of treatment – two regimens are possible based on the bleeding pattern desired1

  • 100mg daily at bedtime (1 capsule) from day 1 to day 25 of the cycle
  • Withdrawal bleeding is less with this schedule

Or

  • 200mg daily at bedtime for 12 days (2 capsules) starting on day 15 of the cycle ending on day 26
Do not take this medicine with food.

References:

1. Utrogestan Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/352/smpc Last accessed: March 2023.
2. Panay N, Post Reprod Health 2014;20(2):69-72.
19. Cyclogest 200mg Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/medicine/15056 Last accessed: March 2023.
20. Cyclogest 400mg Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/5569/smpc Last accessed: March 2023.
21. Crinone Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/1283/smpc Last accessed: March 2023.
22. Lutigest Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/3635 Last accessed: March 2023.
23. Archer DF, et al. Menopause 2012;19(6):622-629.
24. Lindenfeld EA, et al. Obstet Gynecol 2002;100(5 Pt 1):853–863.